CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis Review

Date: March 1, 2016
Pages: 44
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CB3DBAA8B17EN
Leaflet:

Download PDF Leaflet

CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis Review
CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

CEL-SCI Corporation (CEL-SCI) is a biotechnology company which focuses on developing for immunotherapies for the treatment of cancer and other infectious diseases. The company carries out the research and development in finding techniques to activate the immune system. The company’s lead candidate is Multikine (leukocyte interleukin), an investigational immunotherapy against cancer and human papilloma virus (HPV). CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines CEL-2000 and CEL-4000 for rheumatoid arthritis using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform. The company has operations in Vienna, Virginia; and Baltimore, Maryland. CEL-SCI is headquartered in Vienna, Virginia, the US.

CEL-SCI Corporation Key Recent Developments

Feb 09, 2016: CEL-SCI Reports First Quarter Fiscal 2016 Financial Results
Dec 11, 2015: CEL-SCI Reports Fiscal 2015 Financial Results and Clinical & Corporate Developments
Nov 04, 2015: CEL-SCI’s Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health
Aug 07, 2015: CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 Financial Results
May 08, 2015: CEL-SCI Reports Second Quarter Fiscal Year 2015 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

CEL-SCI Corporation - Key Facts
CEL-SCI Corporation - Key Employees
CEL-SCI Corporation - Key Employee Biographies
CEL-SCI Corporation - Major Products and Services
CEL-SCI Corporation - Pharmaceutical Pipeline Products Data
CEL-SCI Corporation, Pipeline Products by Therapy Area
CEL-SCI Corporation, Pipeline Products by Development Phase
CEL-SCI Corporation - History
CEL-SCI Corporation - Company Statement
CEL-SCI Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

CEL-SCI Corporation - Business Description
CEL-SCI Corporation - Corporate Strategy
CEL-SCI Corporation - SWOT Analysis
SWOT Analysis - Overview
CEL-SCI Corporation - Strengths
Strength - Sturdy Research and Development Activities
Strength - Lead Product: Multikine
Strength - Innovative LEAPS Technology
CEL-SCI Corporation - Weaknesses
Weakness - Lack of Marketed Products
CEL-SCI Corporation - Opportunities
Opportunity - Orphan Drug Designation
Opportunity - Market Potential: Head and Neck Cancer
Opportunity - Collaborations
CEL-SCI Corporation - Threats
Threat - Competitive Pressures
Threat - Non-compliance of Government Regulations
Threat - Rapid Technological Changes
CEL-SCI Corporation - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

CEL-SCI Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
CEL-SCI Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
CEL-SCI Corporation, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 09, 2016: CEL-SCI Reports First Quarter Fiscal 2016 Financial Results
Dec 11, 2015: CEL-SCI Reports Fiscal 2015 Financial Results and Clinical & Corporate Developments
Nov 04, 2015: CEL-SCI’s Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health
Aug 07, 2015: CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 Financial Results
May 08, 2015: CEL-SCI Reports Second Quarter Fiscal Year 2015 Financial Results
Feb 06, 2015: CEL-SCI Reports First Quarter 2015 Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

CEL-SCI Corporation, Key Facts
CEL-SCI Corporation, Key Employees
CEL-SCI Corporation, Key Employee Biographies
CEL-SCI Corporation, Major Products and Services
CEL-SCI Corporation, Number of Pipeline Products by Therapy Area
CEL-SCI Corporation, Number of Pipeline Products by Development Stage
CEL-SCI Corporation, Pipeline Products By Therapy Area and Development Phase
CEL-SCI Corporation, History
CEL-SCI Corporation, Subsidiaries
CEL-SCI Corporation, Key Competitors
CEL-SCI Corporation, Ratios based on current share price
CEL-SCI Corporation, Annual Ratios
CEL-SCI Corporation, Interim Ratios
CEL-SCI Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
CEL-SCI Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
CEL-SCI Corporation, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

CEL-SCI Corporation, Pipeline Products by Therapy Area
CEL-SCI Corporation, Pipeline Products by Development Phase
CEL-SCI Corporation, Performance Chart (2011 - 2015)
CEL-SCI Corporation, Ratio Charts
CEL-SCI Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
CEL-SCI Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Biopolymer Innovations, Llc
Sangart, Inc.
Lentigen Corporation
Altea Therapeutics Corporation
Genitope Corporation
Skip to top


Ask Your Question

CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: